IL-12
The tumor-targeted split IL-12 program aims to safely deliver the therapeutic potential of IL-12 by splitting it into inactive components that are specifically directed to the tumor site using tumor-specific antibodies, thereby mitigating systemic toxicities while activating anti-cancer immune responses.